Prostate screening: PSA explained.

Prostate cancer screening uses the prostate-specific antigen (PSA) blood test, sometimes with newer refinements, to identify men who may benefit from further assessment. PSA screening reduces prostate-cancer deaths but also carries a risk of over-diagnosis, so it is a shared decision made with a doctor.

Why PSA screening matters: with nuance

Prostate cancer is common and often slow-growing. PSA can detect it early, but because some detected cancers would never have caused harm, screening involves balancing benefit against the risk of over-diagnosis and over-treatment. Modern practice uses age-specific thresholds and repeat testing rather than a single cut-off.

What the clinical evidence shows

• ERSPC (Schröder et al. NEJM 2009 and long-term follow-up): PSA-based screening reduced prostate-cancer mortality, while highlighting over-diagnosis.
• Refinements: free/total PSA ratio, PSA density and MRI-first pathways improve specificity and reduce unnecessary biopsies.
• Shared decision-making: Australian and international guidance recommends discussing benefits and harms before testing.

Evidence-based reference ranges

PSA is interpreted using age-specific guides (ng/mL); thresholds vary and results are read in context:

Clinical interpretation

• A raised PSA is not a cancer diagnosis. It can reflect benign enlargement, inflammation or recent activity.
• Trends over time and refinements (free/total ratio, PSA density, MRI) matter more than a single value.
• The decision to screen, and how to act on results, should be made with your doctor, weighing benefits and harms.

How this works at HodieLabs

PSA-based prostate screening is available within the Health Blueprint and as an add-on, with results interpreted in context and a clear pathway for any elevation at our Melbourne Preventative Health & Longevity Clinic.

References

1. Schröder FH, et al. (ERSPC). Screening and prostate-cancer mortality in a randomised European study. N Engl J Med. 2009;360:1320–1328.
2. Hugosson J, et al. (ERSPC long-term follow-up). Eur Urol. 2019;76:43–51.
3. Australian guidance recommends shared decision-making for PSA testing.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.